TOP1 and lung carcinoma: The C-terminal domain of Top1 is known to be involved in both enzyme catalytic activity and drug binding [27], and several camptothecin resistance-associated mutations have been reported in the 717–737 region [56–62], including a pair of mutations in a tumor sample from a cisplatin/irinotecan treated lung cancer patient [29].